Risk factor
Weak & very vulnerable to price shocks
Profitability factor
Very low or no dividends
About
Zhejiang Starry Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of X-CT non-ionic contrast agents and fluoroquinolones drugs and intermediates in China and internationally. Its contrast agent products include iohexol, iohexol hydrolysate, iohexol iodide, ioversol, iopamidol, iomeprol, iopromide, cybeclamine, iodixanol, gadopentetic acid dimeglumine, and glutamate; and fluoroquinolones products comprise levofloxacin, levofloxacin hydrochloride,...
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBITD
Buy
Sell